Oncology is one of the fastest-growing segments of drug development and, given the needs of cancer sufferers that aren't met, that's good news. It's also good business. Cancer-fighting drugs did an estimated $75 billion in global sales last year.

With that in mind, this episode of The Motley Fool's Market Checkup tackles the biggest news stories of the week involving cancer drugs, and the companies that make them. Watch and find out the latest on a potential biotech buyout, and which big pharma stock got a surprising result in late-stage trials.

In this video, health-care analysts David Williamson and Max Macaluso discuss Eli Lilly's (NYSE:LLY) recent pipeline success, which caught investors off guard. Find out why this lung cancer drug surprised in phase 3 trials, why the positive news couldn't have come at a better time, and how much investors should be excited as it moves into the FDA review process.

Follow David on Twitter: @MotleyDavid.